All results

14 results for randomized double blind multiple dose placebo controlled study evaluate safety 0

• CTD-TCNPC-301

  A prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 3 and older with confirmed diagnosis of Niemann…

  Ages

  3 Years - N/A

  Sexes

  All

• diSArm

  Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…

  Ages

  18 Years - N/A

  Sexes

  All

• Armata

  Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…

  Ages

  18 Years - N/A

  Sexes

  All

• ATYR

  This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK),…

  Ages

  18 Years - 75 Years

  Sexes

  All

• A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Underg

  An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155…

  Ages

  18 Years - N/A

  Sexes

  All

• A1334-02

  The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants…

  Ages

  18 Years - N/A

  Sexes

  All

• JNT-517

  The goal of Parts A and B of this Phase 1, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD)…

  Ages

  18 Years - 65 Years

  Sexes

  All

• NIH AIM 2 - Low Dose Pioglitazone in NASH

  To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…

  Ages

  21 Years - 75 Years

  Sexes

  All

• ALXN2050-NEPH-201

  This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy…

  Ages

  18 Years - 75 Years

  Sexes

  All

• Vasomune AV001-004

  A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring…

  Ages

  18 Years - N/A

  Sexes

  All